Patients with severe type 2 diabetes (T2D) and obesity exhibit duodenal dysfunction and morphologic changes, similar to ones described above, along with altered glucose absorption physiology leading to enhanced blood glucose, insulin, and glucagon and decreased glucagon-like peptide–1 (GLP-1) (2, 3). This evidence concerns the gene GLP1R and obesity disorder.